EUA
Telepoint SARS-CoV-2 IgG/IgM Rapid Qualitative Test
FDA Emergency Use Authorization · Xiamen Biotime Biotechnology Co., Ltd. · Nov 6, 2020
Key facts
| Product | Telepoint SARS-CoV-2 IgG/IgM Rapid Qualitative Test |
|---|---|
| Company | Xiamen Biotime Biotechnology Co., Ltd. |
| Product type | IgM and IgG, Lateral Flow |
| Date | Nov 6, 2020 |
| FDA page | fda.gov |
At a glance
- 1–9 Authorization documents
- 1–9 EUAs for this company
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Emergency Use Authorizations
Emergency Use Authorizations allow the FDA to permit unapproved medical products, or unapproved uses of approved products, during a declared public health emergency.
Source: U.S. Food and Drug Administration (FDA), Emergency Use Authorizations · Source date: